Global antibody response to Staphylococcus aureus live-cell vaccination.
The pathogen Staphylococcus aureus causes a broad range of severe diseases and is feared for its ability to rapidly develop resistance to antibiotic substances. The increasing number of highly resistant S. aureus infections has accelerated the search for alternative treatment options to close the widening gap in anti-S. aureus therapy. This study analyses the humoral immune response to vaccination of Balb/c mice with sublethal doses of live S. aureus. The elicited antibody pattern in the sera of intravenously and intramuscularly vaccinated mice was determined using of a recently developed protein array. We observed a specific antibody response against a broad set of S. aureus antigens which was stronger following i.v. than i.m. vaccination. Intravenous but not intramuscular vaccination protected mice against an intramuscular challenge infection with a high bacterial dose. Vaccine protection was correlated with the strength of the anti-S. aureus antibody response. This study identified novel vaccine candidates by using protein microarrays as an effective tool and showed that successful vaccination against S. aureus relies on the optimal route of administration.
University Würzburg, Institute for Molecular Infection Biology, Würzburg, Germany.
Martina
M
Selle
University Würzburg, Institute for Molecular Infection Biology, Würzburg, Germany.
Tobias
T
Hertlein
University Würzburg, Institute for Molecular Infection Biology, Würzburg, Germany.
Babett
B
Oesterreich
University Würzburg, Institute for Molecular Infection Biology, Würzburg, Germany.
Theresa
T
Klemm
University Greifswald, Institute for Microbiology, Greifswald, Germany.
Peggy
P
Kloppot
Alere Technologies GmbH, Jena, Germany.|InfectoGnostics Research Campus Jena, Germany.
Elke
E
Müller
Alere Technologies GmbH, Jena, Germany.|InfectoGnostics Research Campus Jena, Germany.
Ralf
R
Ehricht
University Medicine Greifswald, Department of Immunology, Greifswald, Germany.
Sebastian
S
Stentzel
University Medicine Greifswald, Department of Immunology, Greifswald, Germany.
Barbara M
BM
Bröker
Technical University Braunschweig, Institute for Microbiology, Braunschweig, Germany.|Helmholtz-Zentrum für Infektionsforschung, Mikrobielle Proteomik, Braunschweig, Germany.
Susanne
S
Engelmann
University Würzburg, Institute for Molecular Infection Biology, Würzburg, Germany.
Knut
K
Ohlsen
D061605:Administration, Intravenous; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000917:Antibody Formation; D004195:Disease Models, Animal; D007273:Injections, Intramuscular; D008807:Mice, Inbred BALB C; D046228:Microarray Analysis; D040081:Protein Array Analysis; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013209:Staphylococcal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D013211:Staphylococcus aureus / Q000276:immunology*; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology
D000907:Antibodies, Bacterial; D013209:Staphylococcal Vaccines; D014613:Vaccines, Attenuated